Systemic sclerosis associated myopathy.
暂无分享,去创建一个
[1] M. Hudson,et al. Capillary pathology with prominent basement membrane reduplication is the hallmark histopathological feature of scleromyositis , 2022, Neuropathology and applied neurobiology.
[2] G. Espinosa,et al. Clinico-pathological phenotypes of Systemic Sclerosis associated myopathy: analysis of a multicenter large cohort. , 2022, Rheumatology.
[3] M. Nikpour,et al. Using magnetic resonance imaging to map the hidden burden of muscle involvement in systemic sclerosis , 2022, Arthritis Research & Therapy.
[4] C. Bonroy,et al. Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern , 2022, Annals of the Rheumatic Diseases.
[5] L. Mouthon,et al. Quantification of Antifibrillarin (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis , 2021, Diagnostics.
[6] M. Hudson,et al. Histopathological features of systemic sclerosis-associated myopathy: A scoping review. , 2021, Autoimmunity reviews.
[7] H. Goebel,et al. Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology , 2021, Acta Neuropathologica.
[8] C. Campochiaro,et al. The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. , 2021, Rheumatology.
[9] Yan Du,et al. Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis , 2020, Medicine.
[10] D. Theodorou,et al. Myocarditis in Scleroderma: An Underrecognized Manifestation of the Disease. , 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[11] L. Mouthon,et al. Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients. , 2019, Autoimmunity reviews.
[12] R. Sauter,et al. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis , 2019, Annals of the rheumatic diseases.
[13] F. Buttgereit,et al. Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. , 2018, Nutrition.
[14] E. Svenungsson,et al. Muscle endurance, strength, and active range of motion in patients with different subphenotypes in systemic sclerosis: a cross-sectional cohort study , 2018, Scandinavian journal of rheumatology.
[15] Ami A. Shah,et al. Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality , 2017, Arthritis care & research.
[16] M. Cutolo,et al. Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation , 2017, Therapeutic advances in musculoskeletal disease.
[17] E. Ballot,et al. The Clinical Relevance of Antifibrillarin (anti‐U3‐RNP) Autoantibodies in Systemic Sclerosis , 2017, Scandinavian journal of immunology.
[18] J. Paik,et al. Myopathy in scleroderma and in other connective tissue diseases , 2016, Current opinion in rheumatology.
[19] L. Hummers,et al. Severity of muscle weakness independently associates with disability as measured by the Health Assessment Questionnaire‐Disability Index (HAQ‐DI) in scleroderma , 2016 .
[20] M. Hudson,et al. Clinical and Serologic Correlates of Anti‐PM/Scl Antibodies in Systemic Sclerosis: A Multicenter Study of 763 Patients , 2014, Arthritis & rheumatology.
[21] M. Hudson,et al. Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort , 2014, Scandinavian journal of rheumatology.
[22] M. Fujimoto,et al. Autoantibodies to RuvBL1 and RuvBL2: A Novel Systemic Sclerosis–Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement , 2014, Arthritis care & research.
[23] U. Müller-Ladner,et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study , 2012, Annals of the rheumatic diseases.
[24] L. Mouthon,et al. Myopathies related to systemic sclerosis: a case–control study of associated clinical and immunological features , 2010, Scandinavian journal of rheumatology.
[25] L. Mouthon,et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies , 2008, Annals of the rheumatic diseases.
[26] L. Mouthon,et al. Systemic Sclerosis‐Associated Myopathy , 2007, Annals of the New York Academy of Sciences.
[27] U. Müller-Ladner,et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.
[28] T. Medsger,et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.
[29] C. Denton,et al. SYSTEMIC SCLEROSIS , 2008 .